Lindsey Shapiro, PhD, Science Writer —

Throughout May, the U.S. Centers for Disease Control and Prevention (CDC) will work with public health partners to raise awareness of viral hepatitis…

Gilead Sciences has awarded $4 million in funding via its ALL4LIVER grant program to organizations worldwide whose community-based efforts will help the World Health…

FXR314, an investigational oral therapy, safely and effectively reduced liver fat content in adults with a severe form of fatty liver disease called metabolic…

The approval of Rezdiffra (resmetirom) last month in the U.S. as the first ever treatment for nonalcoholic steatohepatitis (NASH), a severe type of…

Five-year-old Sadie Sellers, who was born with biliary atresia, is the focus of a fundraising event designed to raise awareness of and funds for…

Elafibranor, an oral molecule under regulatory review as a new second-line treatment for adults with primary biliary cholangitis (PBC), may become the first candidate…

Chiglitazar (carfloglitazar), an oral medication approved to treat type 2 diabetes in China, led to significant reductions in liver fat accumulation among people with nonalcoholic…

Researchers have identified new strategies for developing a vaccine against hepatitis C by studying the immune responses of a patient who spontaneously cleared three…

Inventiva’s investigational oral therapy lanifibranor safely reduced blood sugar levels and eased signs of liver disease among people with metabolic dysfunction-associated steatohepatitis (MASH), a…

The Center for Disease Analysis (CDA) Foundation has granted $2.1 million in funding to 14 U.S. organizations to help diagnosed but untreated hepatitis…